How would you approach patients receiving neoadjuvant pembrolizumab (SWOG 1801) for melanoma with no response to systemic treatment?

There isn't a definitive answer to this question as patients without a pathologic response tend to have the worst outcomes in terms of relapse-free survival outcomes.

There is no prospective data to support the change in treatment strategy from single agent to dual agent, especially in the absence o...